![Linda Peters](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Linda Peters
Director/Board Member at F3 Platform Biologics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jonathan Peskoff | M | 51 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 6 years |
James Miller | M | 58 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 6 years |
Holger Liepmann | M | 72 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | - |
Bernardus MacHielse | M | 63 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | - |
Kevin Rooney | M | 58 |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 2 years |
Daniel Courchesne | M | - |
F3 Platform Biologics, Inc.
![]() F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | 5 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 6 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Linda Peters
- Personal Network